Advertisement


Toni K. Choueiri, MD, on Cabozantinib vs Everolimus in Patients With Advanced Renal Cell Carcinoma

2015 European Cancer Congress

Advertisement

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses results of the phase III METEOR trial in advanced renal cell carcinoma, which evaluated the efficacy of cabozantinib compared to everolimus in patients with disease progression after VEGFR-targeted therapy (Abstract 4LBA).



Related Videos

Lung Cancer

Jean-Yves Douillard, MD, PhD, on New Perspectives in Small Cell Lung Cancer

Jean-Yves Douillard, MD, PhD, of Centre R Gauducheau, reviews new clinical trials and data on systemic and radiation treatment of small cell lung cancer.

Issues in Oncology
Breast Cancer

Matteo Lambertini, MD, on Preserving Women’s Fertility Through Hormonal Therapy

Matteo Lambertini, MD, Dana-Farber Cancer Institute, discusses the use of LHRH agonists during chemotherapy to suppress ovarian function as a way to preserve fertility in breast cancer patients (Abstract 1957).

Lung Cancer

Jean-Charles Soria, MD, PhD, on Results of the Lux Lung 8 Clinical Trial

Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: afatinib vs erlotinib in squamous cell carcinoma of the lung.

Global Cancer Care

Looking Ahead With the New ECCO President: Peter L. J. Naredi, MD, PhD

Incoming ECCO President, Peter L. J. Naredi, MD, PhD, of the University of Gothenburg, discusses his upcoming year as the new ECCO President, his vision for the organization, and his views on cancer treatment today.

Colorectal Cancer

Michel Ducreux, MD, PhD, on Results of the Phase II COLO 001 Clinical Trial

Michel Ducreux, MD, PhD, of the Institut Gustave Roussy, discusses the efficacy and safety in this study of nab-paclitaxel in patients with previously treated metastatic colorectal cancer (Abstract 2131).

Advertisement

Advertisement




Advertisement